PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1573652
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1573652
Scleroderma Therapeutics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
The Global Scleroderma Therapeutics Market was valued at USD 2.2 billion in 2023 and is projected to grow at a CAGR of 6.8% from 2024 to 2032. This growth is driven by the increasing prevalence of scleroderma and rising patient awareness. The rising incidence of both systemic and localized scleroderma globally is boosting demand for effective treatments. The National Scleroderma Foundation reports that approximately 300,000 Americans are affected by scleroderma, with many cases likely undiagnosed. Increased awareness and earlier diagnosis are further driving demand for specialized treatments. Significant investments in research and development are creating opportunities for market growth.
The overall scleroderma therapeutics industry is classified based on the drug class, indication, route of administration, and region.
The market is segmented by drug class into phosphodiesterase prostacyclin analogs, 5 inhibitors (PHA), immunosuppressors, endothelin receptor antagonists, calcium channel blockers, analgesics, and others. In 2023, the immunosuppressors segment generated the highest revenue of USD 781.6 million. Immunosuppressors dominate the market due to their role in managing systemic scleroderma. These drugs reduce inflammation and fibrosis by suppressing the overactive immune response. Their effectiveness in controlling severe manifestations like lung fibrosis and renal involvement makes them essential in treatment.
By indication, the market is divided into systemic and localized scleroderma. The systemic scleroderma segment led with a revenue of USD 1.9 billion in 2023. Systemic scleroderma holds a larger market share due to its severity and complexity. It affects internal organs and involves widespread fibrosis, leading to significant morbidity and mortality. This drives demand for comprehensive and aggressive treatment strategies. The increasing recognition of systemic scleroderma's impact on quality-of-life fuels the demand for specialized therapeutics. The disease requires a multifaceted approach to address symptoms and complications like pulmonary fibrosis, gastrointestinal issues, and renal involvement.
In 2023, the North American scleroderma therapeutics market generated USD 1.1 billion in revenue and is expected to grow at a CAGR of 5.3% from 2024 to 2032. Demand in North America is rising due to the increasing prevalence of the disease and heightened awareness among healthcare professionals and patients. The region's advanced healthcare infrastructure facilitates early diagnosis and management, boosting demand. North America's strong regulatory framework and supportive policies for orphan drugs encourage the development and approval of scleroderma treatments. Combined with substantial R&D funding, this accelerates the introduction of innovative therapies into the market.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of scleroderma
- 3.2.1.2 Rising patient awareness
- 3.2.1.3 Facilitative government support and initiatives
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 Adverse effects and safety concerns
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Pipeline analysis
- 3.6 Technology landscape
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
- 3.9 Future market trends
- 3.10 Gap analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Company market share analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Immunosuppressors
- 5.3 Phosphodiesterase 5 inhibitors - PHA
- 5.4 Endothelin receptor antagonists
- 5.5 Prostacyclin analogues
- 5.6 Calcium channel blockers
- 5.7 Analgesics
- 5.8 Other drug classes
Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Systemic scleroderma
- 6.3 Localized scleroderma
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Oral
- 7.3 Injectable
- 7.4 Other routes of administrations
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 Actelion (Johnson and Johnson)
- 9.2 Akashi Therapeutics
- 9.3 Astellas Pharma
- 9.4 Bayer AG
- 9.5 Boehringer Ingelheim
- 9.6 Bristol-Myers Squibb
- 9.7 Galderma Laboratories
- 9.8 Genkyotex
- 9.9 Gilead Sciences
- 9.10 GSK plc
- 9.11 Pfizer, Inc.
- 9.12 Prometic Life Sciences, Inc.
- 9.13 F. Hoffmann La Roche Ltd.
- 9.14 Sanofi SA
- 9.15 United Therapeutics
